WuXi PharmaTech

Latest Headlines

Latest Headlines

Former Creighton professor named chief medical officer at 23andMe

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

WuXi poaches an AstraZeneca exec to amp up Chinese R&D

Chinese CRO WuXi PharmaTech has convinced Steve Yang, head of Asian R&D for AstraZeneca, to jump ship, joining the company as it looks to expand its presence in its home country and abroad.

China's WuXi invests in edible anti-counterfeiting tech

Drugmakers are looking for ways to deter counterfeiters, and so contract manufacturers are having to as well. Shanghai-based WuXi PharmaTech intends to provide a solution to its clients.

WuXi bets on anti-counterfeiting tech with an eye on drug safety

WuXi PharmaTech, China's largest pharma outsourcing outfit, is investing in a startup that makes tiny, edible bar codes designed to prevent drug counterfeiting, planning to offer the same technology to its manufacturing customers.

WuXi deepens its genomics might with Illumina, Pacific Biomarkers deals

Fresh off scoring U.S. certification for its genomics lab, China's WuXi PharmaTech is amping up its lab testing services, buying into Illumina's $1,000 genome technology and teaming up with Pacific Biomarkers to broaden its assay menu.

WuXi soars on manufacturing and plots another leap in 2014

WuXi PharmaTech boosted its revenue 15.6% last year, and China's largest CRO is expecting to match that growth in the new year, counting on steady demand for manufacturing and a larger share of the U.S. research market.

AstraZeneca spares its WuXi-partnered drug in an R&D slash and burn

Pharma giant AstraZeneca has pulled the plug on a fleet of its in-development drugs but let live a rheumatoid arthritis treatment being co-developed with Chinese CRO giant WuXi PharmaTech.

WuXi boosts outlook as Chinese CRO market swells

WuXi PharmaTech, China's largest CRO, banked another strong revenue quarter thanks to escalating demand for clinical trials in its home country, and now the company is raising its annual profit expectations by about 7.6%.

WuXi adds two 2000-L bioreactors to Shanghai facility

WuXi PharmaTech says it has expanded a biologics plant in Shanghai by adding two 2,000-liter disposable bioreactors. The facility already has two cell culture suites containing the 500-liter and 1,000-liter disposable bioreactors in operation.

WuXi is first in China with CLIA-OK genomics lab

WuXi PharmaTech won CLIA certification for its Shanghai genomics lab, making it the first such outfit in China to meet U.S. testing standards.